Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.8K

Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas

Teresa Palomero1, Lucile Couronné2, Hossein Khiabanian3

  • 11] Institute for Cancer Genetics, Columbia University, New York, New York, USA. [2] Department of Pathology, Columbia University Medical Center, New York, New York, USA. [3].

Nature Genetics
|January 14, 2014
PubMed

Insights

New genetic mutations in TET2, DNMT3A, IDH2, and RHOA were discovered in peripheral T cell lymphomas (PTCLs). These findings advance our understanding of PTCL pathogenesis and potential therapeutic targets.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Peripheral T cell lymphomas (PTCLs) represent a diverse and inadequately understood category of non-Hodgkin lymphomas.
  • Understanding the genetic underpinnings of PTCL transformation is crucial for developing effective treatments.

Purpose of the Study:

  • To identify novel genetic alterations driving the transformation of PTCLs.
  • To elucidate the functional impact of newly discovered mutations in PTCL pathogenesis.

Main Methods:

  • Whole-exome sequencing of 12 tumor-normal DNA pairs.
  • RNA sequencing analysis.
  • Targeted deep sequencing of PTCL samples.

Main Results:

  • Recurrent mutations in epigenetic factors TET2, DNMT3A, and IDH2 were identified.
  • A prevalent RHOA mutation (p.Gly17Val) was found in 67% of angioimmunoblastic T cell lymphoma (AITL) and 18% of PTCL, not otherwise specified (PTCL-NOS) samples.
  • Mutations in FYN, ATM, B2M, and CD58 were also observed, implicating SRC signaling, DNA damage response, and immune surveillance evasion.

Conclusions:

  • The study identifies key genetic alterations, including RHOA mutations, in PTCL pathogenesis.
  • These findings provide new insights into PTCL biology and suggest potential therapeutic strategies targeting identified pathways.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.4K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.6K